{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:37:03Z","timestamp":1763105823654,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> Chronic drug therapy may impact recurrence and survival of patients with bladder cancer and thus be of concern regarding drug choice and treatment decisions. Currently, data are conflicting for some drug classes and missing for others. <jats:italic>Objective<\/jats:italic> To analyze the impact of common non-oncologic chronic drug intake on survival in patients with bladder cancer and radical cystectomy. <jats:italic>Setting.<\/jats:italic> Patients with bladder cancer and radical cystectomy (2004\u20132018) at the University Hospital Munich. <jats:italic>Method<\/jats:italic> Data from an established internal database with patients with bladder cancer and radical cystectomy were included in a retrospective study. Drug therapy at the time of radical cystectomy and survival data were assessed and follow-up performed 3\u00a0months after radical cystectomy and yearly until death or present. Impact on survival was analyzed for antihypertensive, antidiabetic, anti-gout, antithrombotic drugs and statins, using the Kaplan\u2013Meier method, log-rank test and Cox-regression models. <jats:italic>Main outcome measure<\/jats:italic> Recurrence free survival, cancer specific survival and overall survival for users versus non-users of predefined drug classes. <jats:italic>Results<\/jats:italic> Medication and survival data were available in 972 patients. Median follow-up time was 22\u00a0months (IQR 7\u201361). In the univariate analysis, a significant negative impact among users on recurrence free survival (<jats:italic>n<\/jats:italic>\u2009=\u200993; <jats:italic>p<\/jats:italic>\u2009=\u20090.038), cancer specific survival (<jats:italic>n<\/jats:italic>\u2009=\u2009116; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and overall survival (<jats:italic>n<\/jats:italic>\u2009=\u2009116; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) was found for calcium-channel blockers, whereas angiotensin-receptor-blockers negatively influenced overall survival (<jats:italic>n<\/jats:italic>\u2009=\u200996; <jats:italic>p<\/jats:italic>\u2009=\u20090.020), but not recurrence free survival (<jats:italic>n<\/jats:italic>\u2009=\u200973; <jats:italic>p<\/jats:italic>\u2009=\u20090.696) and cancer specific survival (<jats:italic>n<\/jats:italic>\u2009=\u200996; <jats:italic>p<\/jats:italic>\u2009=\u20090.406). No effect of angiotensin-receptor-blockers and calcium-channel blockers was seen in the multivariate analysis. None of the other studied drugs had an impact on survival. <jats:italic>Conclusion<\/jats:italic> There was no impact on bladder cancer recurrence and survival for any of the analyzed drugs. Considering our results and the controverse findings in the literature, there is currently no evidence to withhold indicated drugs or choose specific drug classes among the evaluated non-oncologic chronic drug therapies. Thus, prospective studies are required for further insight. <jats:italic>Trail registration<\/jats:italic> This is part of the trial DRKS00017080, registered 11.10.2019.<\/jats:p>","DOI":"10.1007\/s11096-021-01343-x","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T11:03:46Z","timestamp":1635764626000},"page":"339-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Retrospective evaluation of the impact of non-oncologic chronic drug therapy on the survival in patients with bladder cancer"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-6974","authenticated-orcid":false,"given":"Lisa","family":"Haimerl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothea","family":"Strobach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Mannell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Karl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"1343_CR1","unstructured":"Babjuk M BM, Comp\u00e9rat E, et al. EAU guideline: non-muscle-invasive bladder cancer. presented at the EAU Annual Congress Barcelona 2019."},{"issue":"5\u20136","key":"1343_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00103-013-1667-8","volume":"56","author":"H Knopf","year":"2013","unstructured":"Knopf H, Grams D. Medication use of adults in Germany: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5\u20136):868\u201377.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"12","key":"1343_CR3","doi-asserted-by":"publisher","first-page":"911","DOI":"10.14740\/jocmr3617w","volume":"10","author":"S Roy","year":"2018","unstructured":"Roy S, Vallepu S, Barrios C, et al. Comparison of comorbid conditions between cancer survivors and age-matched patients without cancer. J Clin Med Res. 2018;10(12):911\u20139.","journal-title":"J Clin Med Res"},{"issue":"4","key":"1343_CR4","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/cam4.1354","volume":"7","author":"H Tang","year":"2018","unstructured":"Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018;7(4):1070\u201380.","journal-title":"Cancer Med"},{"issue":"6","key":"1343_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Jubber I, Black PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74(6):784\u201395.","journal-title":"Eur Urol"},{"issue":"5","key":"1343_CR6","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.juro.2015.05.104","volume":"194","author":"ML Blute Jr","year":"2015","unstructured":"Blute ML Jr, Rushmer TJ, Shi F, et al. Renin-Angiotensin inhibitors decrease recurrence after transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer. J Urol. 2015;194(5):1214\u20139.","journal-title":"J Urol"},{"issue":"12","key":"1343_CR7","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1245\/s10434-012-2568-z","volume":"19","author":"K Yuge","year":"2012","unstructured":"Yuge K, Miyajima A, Tanaka N, et al. Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol. 2012;19(12):3987\u201393.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1343_CR8","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1097\/MD.0000000000000589","volume":"94","author":"F Dal Moro","year":"2015","unstructured":"Dal Moro F, Bovo A, Crestani A, et al. Effect of hypertension on outcomes of high-risk patients after BCG-treated bladder cancer: a single-institution long follow-up cohort study. Med (Baltimore). 2015;94(9):e589.","journal-title":"Med (Baltimore)."},{"issue":"4","key":"1343_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/21681805.2019.1634147","volume":"53","author":"EEE Santala","year":"2019","unstructured":"Santala EEE, Kotsar A, Veitonmaki T, et al. Risk of urothelial cancer death among people using antihypertensive drugs-a cohort study from Finland. Scand J Urol. 2019;53(4):185\u201392.","journal-title":"Scand J Urol"},{"issue":"1","key":"1343_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/HJH.0000000000001130","volume":"35","author":"YW Chuang","year":"2017","unstructured":"Chuang YW, Yu MC, Huang ST, et al. Spironolactone and the risk of urinary tract cancer in patients with hypertension: a nationwide population-based retrospective case-control study. J Hypertens. 2017;35(1):170\u20137.","journal-title":"J Hypertens"},{"issue":"3","key":"1343_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1245\/s10434-016-5534-3","volume":"24","author":"T Yoshida","year":"2017","unstructured":"Yoshida T, Kinoshita H, Fukui K, et al. prognostic impact of renin-angiotensin inhibitors in patients with bladder cancer undergoing radical cystectomy. Ann Surg Oncol. 2017;24(3):823\u201331.","journal-title":"Ann Surg Oncol"},{"key":"1343_CR12","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12885-015-1152-x","volume":"15","author":"A Pastore","year":"2015","unstructured":"Pastore A, Palleschi G, Fuschi A, et al. Can daily intake of aspirin and\/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection. BMC Cancer. 2015;15:120.","journal-title":"BMC Cancer"},{"key":"1343_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bcp.2018.03.008","volume":"151","author":"S Ishikane","year":"2018","unstructured":"Ishikane S, Takahashi-Yanaga F. The role of angiotensin II in cancer metastasis: potential of renin-angiotensin system blockade as a treatment for cancer metastasis. Biochem Pharmacol. 2018;151:96\u2013103.","journal-title":"Biochem Pharmacol"},{"issue":"30","key":"1343_CR14","doi-asserted-by":"publisher","first-page":"e11596","DOI":"10.1097\/MD.0000000000011596","volume":"97","author":"J Hu","year":"2018","unstructured":"Hu J, Chen JB, Cui Y, et al. Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97(30):e11596.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"1343_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5489\/cuaj.4870","volume":"12","author":"PO Richard","year":"2018","unstructured":"Richard PO, Ahmad AE, Bashir S, et al. Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: a populationbased analysis. Can Urol Assoc J. 2018;12(6):203\u201310.","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"1343_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/2211-5463.12583","volume":"9","author":"W Wen","year":"2019","unstructured":"Wen W, Gong J, Wu P, et al. Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis. FEBS Open Bio. 2019;9(3):457\u201367.","journal-title":"FEBS Open Bio"},{"issue":"12","key":"1343_CR17","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamainternmed.2017.5512","volume":"177","author":"GS Haaland","year":"2017","unstructured":"Haaland GS, Falk RS, Straume O, et al. Association of Warfarin use with lower overall cancer incidence among patients older than 50 years. JAMA Intern Med. 2017;177(12):1774\u201380.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"1343_CR18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jbspin.2018.01.008","volume":"85","author":"HC Yang","year":"2018","unstructured":"Yang HC, Nguyen PAA, Islam M, et al. Gout drugs use and risk of cancer: a case-control study. Joint Bone Spine. 2018;85(6):747\u201353.","journal-title":"Joint Bone Spine"},{"issue":"5","key":"1343_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","volume":"13","author":"AM Algra","year":"2012","unstructured":"Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13(5):518\u201327.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1343_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1160\/TH03-08-0553","volume":"91","author":"WA Blumentals","year":"2004","unstructured":"Blumentals WA, Foulis PR, Schwartz SW, et al. Does warfarin therapy influence the risk of bladder cancer? Thromb Haemost. 2004;91(4):801\u20135.","journal-title":"Thromb Haemost"},{"issue":"3","key":"1343_CR21","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/CEJ.0000000000000161","volume":"25","author":"CJ Chen","year":"2016","unstructured":"Chen CJ, Hsieh MC, Liao WT, et al. Allopurinol and the incidence of bladder cancer: a Taiwan national retrospective cohort study. Eur J Cancer Prev. 2016;25(3):216\u201323.","journal-title":"Eur J Cancer Prev"},{"issue":"5","key":"1343_CR22","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00345-015-1680-7","volume":"34","author":"T Grimm","year":"2016","unstructured":"Grimm T, Buchner A, Schneevoigt B, et al. Impact of preoperative hemoglobin and CRP levels on cancer-specific survival in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder: results of a single-center study. World J Urol. 2016;34(5):703\u20138.","journal-title":"World J Urol"},{"issue":"3","key":"1343_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/pcan.2017.14","volume":"20","author":"HJKM Shih","year":"2017","unstructured":"Shih HJKM, Tsai PS, et al. Long-term allopurinol use decreases the risk of prostate cancer in patients with gout: a population-based study. Prostate Cancer Prostatic Dis. 2017;20(3):328\u201333.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"1343_CR24","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.urolonc.2012.06.001","volume":"31","author":"C Shih","year":"2013","unstructured":"Shih C, Hotaling JM, Wright JL, et al. Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and Lifestyle (VITAL) study. Urol Oncol. 2013;31(8):1689\u201395.","journal-title":"Urol Oncol"},{"issue":"5","key":"1343_CR25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.juro.2018.05.119","volume":"200","author":"TD Lyon","year":"2018","unstructured":"Lyon TD, Frank I, Shah PH, et al. The association of aspirin use with survival following radical cystectomy. J Urol. 2018;200(5):1014\u201321.","journal-title":"J Urol"},{"issue":"19","key":"1343_CR26","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"issue":"33","key":"1343_CR27","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104.","journal-title":"Eur Heart J"},{"issue":"2","key":"1343_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/03009734.2018.1473534","volume":"123","author":"VC Kok","year":"2018","unstructured":"Kok VC, Zhang HW, Lin CT, et al. Positive association between hypertension and urinary bladder cancer: epidemiologic evidence involving 79,236 propensity score-matched individuals. Ups J Med Sci. 2018;123(2):109\u201315.","journal-title":"Ups J Med Sci"},{"issue":"4","key":"1343_CR29","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.juro.2017.08.130","volume":"199","author":"Z Klaassen","year":"2018","unstructured":"Klaassen Z, Arora K, Goldberg H, et al. extended venous thromboembolism prophylaxis after radical cystectomy: a call for adherence to current guidelines. J Urol. 2018;199(4):906\u201314.","journal-title":"J Urol"},{"issue":"1","key":"1343_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12894-019-0457-5","volume":"19","author":"Q Wang","year":"2019","unstructured":"Wang Q, Zhang T, Wu J, et al. Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China. BMC Urol. 2019;19(1):24.","journal-title":"BMC Urol"},{"issue":"1","key":"1343_CR31","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1186\/s12885-019-6346-1","volume":"19","author":"RJ Molenaar","year":"2019","unstructured":"Molenaar RJ, van Hattum JW, Brummelhuis IS, et al. Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. BMC Cancer. 2019;19(1):1133.","journal-title":"BMC Cancer"},{"issue":"9","key":"1343_CR32","doi-asserted-by":"publisher","first-page":"38 e67","DOI":"10.1016\/j.urolonc.2015.05.024","volume":"33","author":"M Nayan","year":"2015","unstructured":"Nayan M, Bhindi B, Yu JL, et al. The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urol Oncol. 2015;33(9):38 e67-13.","journal-title":"Urol Oncol"},{"issue":"2","key":"1343_CR33","doi-asserted-by":"publisher","first-page":"E4","DOI":"10.1111\/bju.12150","volume":"112","author":"JJ Crivelli","year":"2013","unstructured":"Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int. 2013;112(2):E4-12.","journal-title":"BJU Int"},{"issue":"2","key":"1343_CR34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.juro.2013.02.003","volume":"190","author":"RD da Silva","year":"2013","unstructured":"da Silva RD, Xylinas E, Kluth L, et al. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol. 2013;190(2):487\u201392.","journal-title":"J Urol"},{"issue":"6","key":"1343_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.urolonc.2016.12.009","volume":"35","author":"PO Richard","year":"2017","unstructured":"Richard PO, Ahmad AE, Bashir S, et al. Effect of statins as a secondary chemopreventive agent among individuals with non-muscle-invasive bladder cancer: a population-based analysis. Urol Oncol. 2017;35(6):342\u20138.","journal-title":"Urol Oncol"},{"issue":"1","key":"1343_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamaoncol.2017.2752","volume":"4","author":"L Emilsson","year":"2018","unstructured":"Emilsson L, Garcia-Albeniz X, Logan RW, et al. Examining bias in studies of statin treatment and survival in patients with cancer. JAMA Oncol. 2018;4(1):63\u201370.","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-021-01343-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:19:50Z","timestamp":1649935190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-021-01343-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1343"],"URL":"https:\/\/doi.org\/10.1007\/s11096-021-01343-x","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"24 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable due to the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}